Charles River announced a multi-program collaboration agreement to apply Logica across several previously undrugged targets in the RS portfolio. Logica is an Artificial Intelligence, or AI, powered drug solution that translates biological insights into optimized assets. Under the collaboration, RS will work closely with the Charles River and Valo Health teams to deploy Logica to discover valuable new medicines to address key unmet needs across a range of disease areas, including cancer immunotherapy, autoimmunity, and inflammatory diseases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRL:
- Charles River initiated with a Market Perform at TD Cowen
- Charles River, PathoQuest validate sequencing viral safety assay as option
- Charles River in HQ plasmid manufacturing deal with Fondazione Telethon
- Charles River price target raised to $245 from $235 at BofA
- Charles River raises FY23 EPS view to $10.30-$10.90 from $9.90-$10.90